ClinicalTrials.gg
Status unknownNCT01788332PINUpdated Oct 26, 2018

Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)

A Phase 2 interventional study of Olaparib and Placebo in Non-small Cell Lung Cancer, sponsored by Lisette Nixon. Status unknown at 20 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-26.

Sponsored by Lisette Nixon · Phase 2, Interventional, and Treatment

How we know · 3 judgments

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 5 under way, 1 of them phase 3. olaparib · Carcinoma, Non-Small-Cell Lung.

Enrollment
9th of 11
70 · median 186
Started
2014
with 1 other
Phase 2
7 of 11
1 open now
Registered
2nd of 11
by date
Lead sponsor
1 of 11
Lisette Nixon

Among the 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung, this one is the 9th largest by enrollment, is one of 2 that started in 2014, is one of 7 in phase 2, and was the 2nd registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

2 of the 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing olaparib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

In 2010, more than 35,000 people died in the United Kingdom from lung cancer, the majority from non-small cell cancer (NSCLC). Chemotherapy is one of the main treatments for patients with NSCLC but those treated will still only live for an average of 9 or 10 months after diagnosis.

The purpose of this clinical trial is to find out whether or not giving a drug called Olaparib following chemotherapy will benefit patients with NSCLC who have responded to initial chemotherapy treatment by prolonging the time before the tumour regrows. Olaparib is a new, oral drug developed by AstraZeneca which may help to slow down cancer growth. The rationale for this clinical trial is that chemotherapy damages tumour cell DNA and NSCLC tumours that respond to chemotherapy are less able to repair this damage. This can be exploited by using Olaparib as it blocks an enzyme called Poly (ADP-ribose) polymerase (PARP) which is essential for DNA repair. This will prevent DNA repair and cause cancer cell death by a mechanism known as synthetic lethality. Synthetic lethality arises when a combination of mutation in two or more genes leads to cell death.

Up to 300 patients who are to receive standard chemotherapy treatment will be initially registered into the trial. Of these patients, 114 patients who have responded to chemotherapy will be randomly allocated to receive either Olaparib or an inactive dummy pill or placebo by mouth. The trial will assess whether Olaparib delays disease progression following standard chemotherapy treatment in patients. It will also show whether the side effects of adding Olaparib following standard treatment are acceptable.

Read the detailed description

This is a multicentre randomised phase II trial. Patients are initially registered either before or during induction chemotherapy, their response to which will be used to determine whether they are eligible for randomisation. All patients will be asked to consent to archival tissue collection for translational analysis and to provide a translational blood sample. The second consent will precede randomisation to one of two groups of maintenance therapy (olaparib or placebo) with 1:1 randomisation if they have had an objectively measured complete or partial response following standard chemotherapy.

Randomised patients will receive olaparib or placebo until disease progression. They will be monitored by CT scan every two cycles until disease progression, where they will be managed according to local practice. Follow up will be for a maximum of 12 months from the point of randomisation or until disease progression.

All randomised patients for whom we have a baseline translational blood sample will be asked to provide a follow up blood sample upon randomisation and again at radiological progression. Registered patients with progressive disease after the initial induction chemotherapy will be asked to provide a follow-up blood sample at the end of induction chemotherapy.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • NSCLC
  • non-small cell
  • lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria - Registration (Stage 1):

  • Histological diagnosis of NSCLC. Histology can be either squamous or non-squamous.
  • Stage IIIB or stage IV lung cancer that is not amenable to curative therapy.
  • Have had no prior systemic chemotherapy for advanced NSCLC. Previous or neoadjuvant chemotherapy for non-advanced disease is acceptable. Prior treatment with an oral targeted therapy for e.g. EGFR/ALK or other driver- oncogene mutated lung cancer is allowed. Immunotherapy e.g. with a PD1 or PDL1 targeted agent is allowed.
  • Patients who have already started their induction chemotherapy are not eligible for stage 1 of the trial
  • Eligible to receive standard platinum doublet-based chemotherapy.
  • Men or women, aged 18 or over and capable of giving .
  • Willing to consent to provide tissue and blood for translational research.
  • Informed consent prior to any study specific procedures.

Exclusion Criteria - Registration (Stage 1):

  • Evidence of small cell, large cell neuroendocrine or carcinoid histology.
  • Have a serious or uncontrolled medical condition that could compromise the patients' ability to adhere to the protocol.
  • Have a secondary (except adequately treated non-melanomatous skin cancer, or other cancer considered cured by surgical resection or radiation). Patients who have had another malignancy in the past but have been disease free for more than 5 years are eligible.
  • Previous treatment with PARP inhibitors
  • Uncontrolled gastrointestinal disorders such as active diverticulitis or colitis, or any major GI resection which could have an impact on patients' ability to absorb Olaparib.
  • Myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML).

Inclusion Criteria - Randomisation (Stage 2):

  • Confirmed diagnosis of NSCLC (either squamous or non-squamous). Stage IIIB or stage IV that is not amenable to curative therapy.
  • performance status 0-1
  • Evidence of radiological response to induction chemotherapy, from the pre-treatment to baseline. This can include mixed stable/response or evidence of tumour shrinkage that does not reach the criteria of partial response according to .
  • Have had no prior systemic chemotherapy for advanced NSCLC. Previous adjuvant or neoadjuvant chemotherapy for non-advanced disease is acceptable. Previous palliative radiotherapy to non-target is allowed provided no more than 25% of the bone marrow volume is irradiated. Irradiated sites cannot include the sites of unless clear tumour progression has been documented in them since the end of radiation therapy. Patients who have had adjuvant therapy and then progressed after a year of completing adjuvant therapy are eligible. Patients who have received an oral inhibitor for molecularly stratified subgroups e.g. EGFR or ALK mutated lung cancer, are allowed. Immunotherapy e.g. with a PD1 or PDL1 targeted agent is allowed.
  • Adequate organ function, including the following:

    1. Adequate bone marrow reserve: White cell count ≥ 3.0 x 109/L, (ANC) ≥ 1.5 x 109/L, ≥ 100 x 109/L, ≥ 90g/L.
    2. Hepatic: total ≤ 1.5 times the (x ULN); alkaline phosphatase (ALP), (AST), or alanine aminotransferase (ALT) ≤ 2.5 x ULN. ALP, AST, and ALT ≤ 5 x ULN is acceptable if the liver has tumour involvement.
    3. Renal: calculated (CrCl) ≥ 50mL/min using Cockcroft-Gault or Wright formula, serum creatinine ≤ 1.5 x institutional upper limit of normal (ULN).
    4. If blood count/morphology suggestive of MDS/AML, no features suggestive of MDS/AML on peripheral blood smear.
  • Patients with (male or female), who are sexually active for the duration of the trial or the drug , should be prepared to use two effective forms of .
  • Men or women, aged 18 or over.
  • Willing to consent to provide tissue and blood for translational research.
  • Patients must provide informed consent prior to any study specific procedures.
  • There should be no more than 42 days between day 1 of the last cycle of induction chemotherapy and starting Olaparib/placebo.

Exclusion Criteria - Randomisation (Stage 2):

  • Evidence of small cell, large cell neuroendocrine or carcinoid histology.
  • Patients with radiological disease progression or stable disease after induction chemotherapy
  • Have received treatment with an agent that has not received regulatory approval, within 30 days of study entry.
  • Have had a blood transfusion within 28 days prior to commencing Olaparib or have a WBC \<3 x 109/L
  • Have received yellow fever vaccination in the 30 days prior to randomisation.
  • Difficulty swallowing.
  • Have central nervous system (CNS) metastases (unless the patient has completed successful local therapy for e.g. involving complete surgical removal or radical radiotherapy to a solitary CNS metastasis). A
  • Concurrent administration of any other systemic antitumour therapy.
  • Have a serious or uncontrolled medical condition that would compromise the patient's ability to adhere to the protocol.
  • Diagnosis of a second malignancy (except adequately treated non-melanomatous skin cancer, or other cancer that is considered cured by surgical resection or radiation). Patient who had another malignancy in the past but have been disease free for more than 5 years are eligible.
  • Previous treatment with PARP inhibitors.
  • Uncontrolled gastrointestinal disorders such as active diverticulitis or colitis, or any major GI resection which could have an impact on patients' ability to absorb Olaparib.
  • Myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML).
  • Pregnant or breastfeeding.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Active comparator
    Olaparib

    3 100mg tablets to be administered twice a day with approximately 240ml of water.

    Drug: Olaparib

  • Placebo comparator
    Placebo

    3 100mg tablets to be administered twice a day with approximately 240ml of water.

    Other: Placebo

Interventions

  • Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.

    Also known as: AZD2281, KU-0059436

  • OtherPlacebo

    3 100mg tablets to be administered twice a day with approximately 240ml of water

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    To establish the anti-tumour activity of Olaparib (measured by progression free survival),we will document the time from randomisation to any disease progression and/or death, defined according to strict RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Lesions will be compared to baseline measurements to assess progression.

    Time frame: 72 weeks

Secondary outcomes

  1. Safety

    An Independent Data Monitoring Committee will convene and assess safety when 10 and 20 patients on each arm have completed trial treatment. If the trial is deemed safe to continue then safety will be assessed again approximately every six months. Toxicity data will be assessed along with serious adverse events.

    Time frame: 72 weeks

  2. Objective response rate

    This will be assessed based on radiological disease progression defined according to RECIST (Response Evaluation Criteria in Solid Tumours) v1.1.

    Time frame: 72 weeks

  3. Overall survival

    This will be calculated from the time of randomisation to date of death or date last known to be alive.

    Time frame: 72 weeks

  4. Change in tumour volume reduction

    Change in tumour volume reduction from randomisation to 6 months

    Time frame: 27 weeks

  5. Tolerability

    This will be assessed in terms of the number of treatment reductions, delays and withdrawals.

    Time frame: 72 weeks

  6. Feasibility

    Patients will complete a diary card every day to document compliance. Feasibility of use will also be assessed in terms of number of treatment reductions, delays and withdrawals.

    Time frame: 72 weeks

07

Study locations

20 sites
  • Blackpool Victoria Hospital
    Blackpool, United Kingdom
  • Bradford Royal Infirmary
    Bradford, United Kingdom
  • Queen's Hospital
    Burton Upon Trent, United Kingdom
  • Velindre Cancer Centre
    Cardiff, United Kingdom
  • University Hospitals Coventry and Warwickshire NHS Trust
    Coventry, United Kingdom
  • Derby Teaching Hospitals NHS Foundation Trust
    Derby, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, United Kingdom
  • Withybush General Hospital
    Haverfordwest, United Kingdom
  • Huddersfield Royal Infirmary
    Huddersfield, United Kingdom
  • University Hospitals of Morecambe Bay
    Lancashire, United Kingdom
  • St James University Hospital
    Leeds, United Kingdom
  • Leicester Royal Infirmary
    Leicester, United Kingdom
  • Charing Cross Hospital
    London, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, United Kingdom
  • The James Cook University Hospital
    Middlesbrough, United Kingdom
  • Royal Preston Hospital
    Preston, United Kingdom
  • Weston Park Hospital
    Sheffield, United Kingdom
  • University Hospitals of North Midlands
    Stoke-on-Trent, United Kingdom
  • Singleton Hospital
    Swansea, United Kingdom
  • Wrexham Maelor Hospital
    Wrexham, United Kingdom
08

References and documents

Publications

  • Fennell DA, Porter C, Lester J, Danson S, Blackhall F, Nicolson M, Nixon L, Gardner G, White A, Griffiths G, Casbard A. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine. 2022 Aug 11;52:101595. doi: 10.1016/j.eclinm.2022.101595. eCollection 2022 Oct. PubMed 35990583 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2014 (actual). Primary completion is estimated for Dec 2018, 59 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 59 months is close to that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2013
First posted
Feb 11, 2013
StartActual
Jan 2014
Primary completionEst.
Dec 2018
CompletionEst.
Dec 2018
Last update
Oct 26, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01788332
Lead sponsor
Lisette Nixon
Collaborators
AstraZeneca
Responsible party
Lisette Nixon (Senior Trial Manager, Velindre NHS Trust) — Sponsor-investigator
First posted
Feb 11, 2013
Start date
Jan 2014
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Oct 26, 2018

Study contacts

Dean Fennell, Professor
study chair · University of Leicester

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion